Successful conservative treatment of neutropenic enterocolitis complicating taxane-based chemotherapy: a report of five cases.
Five cases of acute neutropenic enterocolitis complicating taxane-based chemotherapy are described. During a 34-month period, our department administered 4,600 courses of taxane-based (paclitaxel and docetaxel) chemotherapy to 800 cancer patients. Seven to 10 days postchemotherapy in five patients (0.1% of the given courses), neutropenic fever, abdominal pain, rebound tenderness, and grade II-IV diarrhea (bloody in two cases) developed. Two patients had oral candidiasis, and in two others septic shock developed. Computed tomography scans of the abdomen revealed in all patients thickening of the colon wall and pericolic edema, and a pericolic abscess was revealed in three of them. Both clinical and radiologic findings supported the diagnosis of acute neutropenic enterocolitis. All patients were successfully treated with broad-spectrum antibiotics and recombinant human granulocyte colony-stimulating factor. In conclusion, acute neutropenic enterocolitis is a severe complication of taxane-based chemotherapy. Early diagnosis and appropriate conservative treatment leads to complete recovery. Although rare, this infection is less often associated with other chemotherapeutic regimens.
Kouroussis
C
C
Department of Medical Oncology, School of Medicine, University of Crete, Heraklion, Greece.
Samonis
G
G
Androulakis
N
N
Souglakos
J
J
Voloudaki
A
A
Dimopoulos
M A
MA
Kotsakis
T
T
Kakolyris
S
S
Kalbakis
K
K
Georgoulias
V
V
D000208:Acute Disease; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D000077143:Docetaxel; D004760:Enterocolitis / Q000139:chemically induced* / Q000188:drug therapy; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced* / Q000188:drug therapy; D010051:Ovarian Neoplasms / Q000188:drug therapy; D017239:Paclitaxel / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011994:Recombinant Proteins; D043823:Taxoids; D014057:Tomography, X-Ray Computed
D000900:Anti-Bacterial Agents; D000972:Antineoplastic Agents, Phytogenic; D011994:Recombinant Proteins; D043823:Taxoids; D016179:Granulocyte Colony-Stimulating Factor; D000077143:Docetaxel; D017239:Paclitaxel